Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study

To compare 2.0 mg ranibizumab (RBZ) injections with 0.5 mg RBZ for eyes with center-involved diabetic macular edema (DME). Randomized, controlled, double-masked (to the dose), interventional, multicenter clinical trial. A total of 152 patients (152 eyes) with DME. Eligible eyes were randomized in a...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Ophthalmology (Rochester, Minn.) Ročník 123; číslo 12; s. 2581
Hlavní autori:	Sepah, Yasir J, Sadiq, Mohammad Ali, Boyer, David, Callanan, David, Gallemore, Ron, Bennett, Michael, Marcus, Dennis, Halperin, Lawrence, Hassan, Muhammad, Campochiaro, Peter A, Nguyen, Quan Dong, Do, Diana V
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.12.2016
Predmet:	Adult Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Diabetic Retinopathy - drug therapy Diabetic Retinopathy - physiopathology Double-Blind Method Female Follow-Up Studies Humans Intravitreal Injections Macula Lutea - drug effects Macular Edema - drug therapy Macular Edema - physiopathology Male Middle Aged Ranibizumab - administration & dosage Ranibizumab - adverse effects Retreatment Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - drug effects Visual Acuity - physiology
ISSN:	1549-4713, 1549-4713
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!